LivaNova PLC (NASDAQ:LIVN) is one of the 12 Best UK Stocks to Buy According to Hedge Funds. On March 19, 2026, LivaNova PLC (NASDAQ:LIVN) announced that the FDA granted premarket approval for its aura6000 System for treating adults with moderate to severe obstructive sleep apnea. The system uses proximal hypoglossal nerve stimulation to address patients with an apnea-hypopnea index of 15 to 65 who are unable to use or do not respond to first-line therapies such as positive airway pressure. Last month, B ...

Key Takeaways LivaNova received FDA approval for aura6000 to treat moderate to severe OSA in adults.LIVN's p-HGNS therapy showed reduced apnea events and sustained benefits in the OSPREY trial.LIVN's device expands treatment options and supports future growth with next-gen system plans.LivaNova (LIVN) recently received premarket approval from the FDA for its aura6000 system to treat adults with moderate to severe Obstructive Sleep Apnea (OSA). The system uses proximal hypoglossal nerve stimulation (p-HGNS), ...

Core Viewpoint - LivaNova (LIVN) is experiencing significant selling pressure, with a 7.2% decline over the past four weeks, but is positioned for a potential trend reversal as it enters oversold territory, supported by analyst expectations of better earnings than previously predicted [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that indicates whether a stock is oversold, with readings below 30 typically signaling this condition [2]. - LIVN's current RSI reading is 27.99, suggesting that heavy selling may be exhausting itself, indicating a potential bounce back towards equilibrium in supply and demand [5]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that earnings estimates for LIVN have increased by 2.3% over the last 30 days, which often correlates with price appreciation in the near term [7]. - LIVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8].

Core Viewpoint - LivaNova (LIVN) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which are crucial for stock price movements [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is effective for individual investors as it focuses on earnings estimate revisions, which are strongly correlated with near-term stock price movements [2][4]. - The recent upgrade for LivaNova reflects an improvement in its underlying business, suggesting that investor sentiment may lead to increased stock prices [5][10]. Earnings Estimate Revisions - LivaNova is projected to earn $4.18 per share for the fiscal year ending December 2026, with no year-over-year change expected [8]. - Over the past three months, the Zacks Consensus Estimate for LivaNova has increased by 3.7%, indicating a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a "Strong Buy" or "Buy" rating, highlighting superior earnings estimate revisions [9][10]. - LivaNova's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Group 1 - Aston Martin will cut up to 20% of its workforce, resulting in annualized savings of about 40 million pounds ($54 million) [1][2] - The company employs approximately 3,000 workers, and the cuts include a previously announced 5% workforce reduction [2] - Aston Martin is reducing its five-year capital spending plan from 2 billion pounds to 1.7 billion pounds, delaying investments in electric vehicle technology [2] Group 2 - The company has struggled with cash generation and managing its debt, which stands at 1.38 billion pounds [5] - U.S. tariffs have been described as "extremely disruptive," and demand in China has been "extremely subdued" [8] - Aston Martin expects further cash outflows in 2026 but anticipates "material improvement" in financial performance, targeting gross margins in the high 30% range [8] Group 3 - The company reported an operating loss of 259.2 million pounds in 2025 [11] - Recently, Aston Martin struck a 50-million-pound deal to sell the perpetual branding rights to its Formula One team as part of its financial improvement efforts [11]

Financial Performance - LivaNova reported a total revenue of $1.2 billion for the fiscal year ended December 31, 2023, representing a 10% increase compared to the previous year[7]. - The company achieved a gross margin of 65%, up from 62% in 2022, indicating improved operational efficiency[7]. - LivaNova's net revenue for the year ended December 31, 2025, was distributed as follows: 53% from the U.S., 19% from Europe, and 28% from the Rest of the World[48]. - LivaNova reported a total revenue of $1.2 billion for the year ended December 31, 2022, representing a 10% increase compared to the previous year[16]. - The company reported a net income of $150 million for 2022, reflecting a 5% increase from the previous year[16]. Research and Development - LivaNova's R&D expenses increased to $150 million, accounting for 12.5% of total revenue, as the company focuses on new product development and innovation[7]. - LivaNova is investing $100 million in R&D for new product development, including advancements in VNS Therapy and new Cardiopulmonary devices[16]. - LivaNova's R&D investment emphasizes technological advancements, including AI and software improvements, to maintain market leadership[45]. - LivaNova's R&D investment focuses on product design, technology, AI, and clinical study programs to maintain market leadership and address unmet patient needs[45]. - In June 2025, LivaNova completed the CORE-VNS study, reporting 36-month data showing reductions in seizure frequency among individuals with DRE treated with VNS Therapy[36]. - In 2024, preliminary results from the RECOVER clinical study for unipolar depression did not meet primary endpoints but showed significant improvements in secondary endpoints related to quality of life[40]. Market Strategy and Expansion - The company plans to expand its market presence in Asia, targeting a 20% growth in that region by 2025[7]. - LivaNova's market expansion strategy includes entering three new international markets by the end of 2024, targeting a 10% market share in each[16]. - LivaNova has initiated a restructuring plan aimed at enhancing focus on its core Cardiopulmonary and Neuromodulation segments, expected to yield $50 million in annual savings[7]. - The company plans to initiate a restructuring plan in Q1 2024 to enhance focus on its core segments, aiming for a 20% reduction in operational costs by 2025[16]. - LivaNova's commitment to sustainability includes a goal to reduce carbon emissions by 30% by 2025, aligning with global environmental standards[7]. Product Development and Innovation - User data showed a 15% increase in the adoption of VNS Therapy systems, with over 50,000 patients treated globally[7]. - LivaNova's new product launch, the Hemolung Respiratory Assist System, is projected to generate $100 million in revenue within the first two years of its release[7]. - The Cardiopulmonary segment includes products such as HLMs, oxygenators, and autotransfusion systems, which are essential for various heart-related medical procedures[25][26]. - The Neuromodulation segment focuses on devices for treating drug-resistant epilepsy (DRE) and treatment-resistant depression (DTD), including the VNS Therapy System[31][33]. - The company received FDA approval for the aura6000 System for obstructive sleep apnea (OSA) and announced that the OSPREY clinical trial met its primary endpoints for efficacy and safety in 2024[42][43]. Competitive Landscape - The company faces increasing competitive pressure leading to downward pricing trends as hospitals seek to reduce costs through centralized purchasing and limiting vendor participation[51]. - LivaNova's primary competitors in the Cardiopulmonary and Neuromodulation product groups include Terumo Medical Corporation, Medtronic plc, and Haemonetics Corporation[54]. Regulatory Compliance - LivaNova must comply with extensive government regulations for product approval, including the FDA's 510(k) clearance and PMA processes, which can be costly and time-consuming[57]. - The EU's MDR requires compliance by December 2027 or 2028, with penalties for non-compliance potentially including fines and revocation of marketing authorization[58]. - Under GDPR, LivaNova faces potential fines of up to €20 million ($23.5 million) or 4% of total worldwide annual net revenue for non-compliance with data protection regulations[65]. - The company is subject to various environmental regulations that may increase compliance costs and expose it to liabilities related to hazardous substances[66]. - LivaNova's operations are governed by anti-corruption laws such as the FCPA and the UK Bribery Act, which could lead to civil or criminal sanctions if violated[68]. Employee Engagement and Corporate Culture - The company had approximately 3,300 employees worldwide as of December 31, 2025, representing over 80 nationalities[82]. - Over 94% of employees participated in the most recent engagement survey, indicating strong employee engagement and satisfaction[85]. - LivaNova's proactive talent acquisition strategies and competitive compensation have been significant drivers of the company's success[83]. - The company is committed to maintaining a diverse and inclusive workplace, supporting various employee affinity initiatives[90]. - LivaNova's performance management process aims to enhance employee skills and capabilities through regular feedback and training[86]. Economic and Market Conditions - The company continues to monitor economic developments, including inflation and raw material costs, which may impact production costs and pricing behavior[71]. - LivaNova is subject to various healthcare regulations, including the Anti-Kickback Statute and False Claims Act, which impose significant compliance costs[79]. - The company employs a multifactorial approach to price setting to reflect the value of its specialized products while providing cost efficiencies to customers[71]. - LivaNova's products are subject to approval from third-party payers for coverage and reimbursement, impacting demand for new devices[70].

Core Insights - LivaNova reported revenue of $360.9 million for the quarter ended December 2025, reflecting a year-over-year increase of 12.2% [1] - The company's EPS for the quarter was $0.86, up from $0.81 in the same quarter last year, exceeding the consensus estimate of $0.80 by 7.06% [1] - The revenue surpassed the Zacks Consensus Estimate of $350.93 million, resulting in a positive surprise of 2.84% [1] Financial Performance - Net Sales in the Neuromodulation segment reached $152.7 million, exceeding the average estimate of $149.13 million [4] - Net Sales in the Cardiopulmonary segment were $206.6 million, surpassing the average estimate of $200.66 million [4] - Net Sales in the Other category amounted to $1.6 million, slightly below the average estimate of $1.89 million [4] Stock Performance - LivaNova's shares have returned +7.7% over the past month, contrasting with a -0.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - The company experienced its third consecutive year of double-digit organic revenue growth in 2025, primarily driven by the rollout of the Essence heart-lung machine (HLM) and market share gains in cardiopulmonary consumables [1] - The cardiopulmonary segment's growth is supported by a global upgrade cycle, with Essence accounting for 55% of HLM units in 2025 and expected to reach 80% of new placements by 2026 [1] - The growth in epilepsy treatment is attributed to strong commercial execution and the CORE VNS study, which is repositioning VNS Therapy earlier in the treatment algorithm for drug-resistant epilepsy [1] Strategic Shifts - The company is undergoing a significant strategic shift from focusing on legacy core businesses to targeting high-margin, high-growth markets such as obstructive sleep apnea (OSA) [1] - Operational capacity for oxygenators is being expanded to meet demand that currently exceeds market supply, supported by internal manufacturing and third-party component partnerships [1] - A 'Connected Care' digital strategy is being implemented, utilizing a single shared cloud platform across all business segments to streamline physician workflows and enhance patient insights [1]

Core Insights - LivaNova PLC is a key player in the medical device industry, focusing on Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments, with a commitment to innovative therapeutic solutions globally [1] Financial Performance - LivaNova reported fourth-quarter revenue of $360.9 million, reflecting a 12.1% increase from the previous year, indicating strong financial performance [3][6] - The U.S. GAAP diluted earnings per share for the fourth quarter was $0.56, further supporting the positive financial outlook [3] Price Target Trends - The consensus price target for LivaNova's stock has risen to an average of $85, up from $74.33 three months ago and $69.63 a year ago, indicating growing analyst confidence [2][6] - Analyst firm Robert W. Baird has set a price target of $75, aligning with the company's strong financial performance and strategic initiatives [5] Strategic Initiatives - LivaNova's collaboration with Verily to capture clinical biomarkers of depression is expected to enhance its product offerings and market position [4][6] - The company's presentation at the American Epilepsy Society Annual Meeting underscores its commitment to advancing medical technology [4][6]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $361 million, a 9.5% increase on a constant currency and organic basis compared to the prior year [22] - Adjusted diluted earnings per share rose to $0.86 from $0.81 in Q4 2024, reflecting strong revenue growth and effective cost management [24] - Cash balance increased to $636 million from $429 million at year-end 2024, driven by improved operating cash flows [26] - Total debt decreased to $377 million from $628 million at year-end 2024 due to early repayments [26] Business Line Data and Key Metrics Changes - Cardiopulmonary segment revenue was $207 million in Q4 2025, a 10% increase year-over-year, with full-year revenue growing 13% [8] - Epilepsy segment revenue increased by 9% in Q4 2025, with full-year growth of 6%, supported by strong commercial execution globally [10][11] Market Data and Key Metrics Changes - U.S. Epilepsy revenue grew 8% year-over-year, while Europe and Rest of World regions combined saw a 17% increase [10] - The heart-lung machine (HLM) revenue grew in the mid-single digits in Q4 2025, with full-year revenue growth in the mid-teens [8] Company Strategy and Development Direction - The company aims to transform into a best-in-class med tech company, focusing on high-growth markets like obstructive sleep apnea (OSA) and leveraging competitive advantages [6][7] - Investments in innovation, digital platforms, and leadership upgrades are being prioritized to support strategic execution [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver sustained value for shareholders, highlighting the durability of core businesses and the potential for growth in new markets [32][34] - The company anticipates revenue growth of 6% to 7% for 2026, consistent with the 2025-2028 framework [28][31] Other Important Information - The company received FDA approval for its cloud-based digital health platform, which will enhance connected care in epilepsy [15] - The reimbursement for VNS Therapy procedures under Medicare increased significantly, which is expected to improve hospital economics and patient access [12] Q&A Session Summary Question: Insights on cardiopulmonary growth guidance for FY 2026 - Management expects continued growth drivers from Essenz upgrades, market share gains, and pricing strategies, with a moderation in price premium for Essenz [36][37] Question: Clarification on epilepsy business guidance - Management noted significant tailwinds from improved reimbursement and clinical evidence, which are expected to support growth in the epilepsy business [42][43] Question: Impact of reimbursement changes on VNS business - Management indicated that they have not seen any denials in the cohorts tracked, and the reimbursement changes are expected to support penetration of new patient implants [50] Question: Specifics on tender timing and geographic impact - Management confirmed that the shift in placements was immaterial and will be fully captured in Q1 2026, with optimism about the launch in China [52][53] Question: Updates on Medicaid reimbursement changes - Management stated that Medicaid is expected to follow Medicare reimbursement levels, although it may take time to work through state-level adjustments [82]